expect pipelin
quarter in-lin estim
shake close model posit
go offens financi posit pipelin delay
suggest catalyst may contribut time
frame extent mani investor expect
quarter in-lin model yet street expect
deliv consist quarter vs model total revenu vs
mse lock-step preview see revenu came
significantli consensu estim broadli updat
reflect impact bulk purchas headwind segment result
larg in-lin expect cvg revenu vs
mse rtg vs mse mitg vs mse
differ driven stronger ou surgic diabet vs
mse rel top-line upsid drove bottom line vs mse gross
margin pt mse pt street oper margin
pt higher materi lower sg spend drive ep vs
model tax slightli lower ep drive ep
slightli model expect provid
formal quarterli annual long-rang guidanc today discuss
driver share perform follow call reflect
confus around recoveri dynam reaction hugo
delay discuss
wors revenu growth vs organ growth well opex
rise quarter larg forecast spend dynam
factor modest revenu improv adjust model
slightli lower organ declin previous three
dynam
region improv week pressur vs manag
comfort identifi april trough busi
may track slightli ahead region china saw
y/i declin februari march follow declin
medic technolog unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
april y/i declin today western europ saw
april declin see declin thu far may us
manag confid procedur improv may
track y/i vs challeng april net analysi suggest
may growth track vs suggest conservat
given like improv trend juli rest-of-world
region less certain given japan exhibit assumpt
bulk purchas less relev still factor bulk purchas
histor promin april toward end
fiscal year mean quarter lack dynam
sens typic see pt bulk purchas
assum major revenu foregon quarter
pocket upsid benefit two clear posit benefit
diabet suppli stock estim drove
increment sale upsid respiratori patient monitor
like drove increment sale across ventil
puls oximet capnographi expect greater upsid
discuss ventil math note model
deliv hsd growth due strong demand dialysi cathet
expect renal remain rel insul beyond
sens manag commentari region declin appli
across segment april press releas therefor see
respiratori upsid worth pt factor total
impact case would drive quarterli organ
declin closer
consid dynam well manag intent continu
grow opex model move revenu
ep given manag commentari gradual
sequenti improv year mid singl digit stack
revenu growth adjust revenu slightli higher
respect maintain drop-through lost
revenu vs pre-covid model sens oper margin like
recov toward normal level exit year net model
total revenu gross margin oper margin
ep seeexhibit summari model chang
rest world
region impact
region revenu
mse bulk purchas impact quarter
pipelin delay focu awar on-m trial delay
impact renal denerv see off-m trial discuss spyral dcf
analysi delay surgic robot hugo wors
expect
hugo like delay month given challeng engin
work remot limit avail work
extern partner site test septemb analyst day see
thought outlin expect ou hugo
placement ce mark file us initi mid
see first placement ce mark file late
earli mid-to-l us initi follow like
late prior model assumpt call revenu
impact mitg bp bp bp
respect bp
corpor see month shift contribut
launch europ quarter signifi delay vs
origin expect like financi materi given us
launch definit delay month anticip
delay januari see timelin slip us delay leav
greater opportun tandem control-iq gain pump share
year ahead put new timelin roughli in-lin insulet
horizon previous expect month lead
manag also suggest pivot data may necessarili meet
origin tir goal outlin ada given target
set prior trial design
sensor updat continu question whether launch
alon help close gap diabet peer given lag
sensor technolog today call confirm concern
like file fda sever month synergi
anticip icgm like file year see possibl
fda approv tidepool loop allow pump connect
extern icgm ahead intern icgm
approv though discuss see recent
dexcom ceo seri like work done medtron
part technolog oper seamlessli
potenti magnitud pipeline-driven top-line upsid
debat stock past month less
bullish consensu pipelin contribut given visibl evidenc
quarter see stock reaction pipelin updat rel warrant
given investor like nearer-term expect catalyst
strong balanc sheet phase posit drive neutral posit risk-
reward prior quarter suggest risk-reward
earn rel neutral slightli posit given recent share
under-perform vs medic devic share
perform follow call like justifi given pipelin
comment entir factor given phase posit see
origin roadmap see opportun
close gap procedure-bas peer next quarter
impact sever other continu
hold one strongest balanc sheet coverag
 invest end whether compani offens posit
bear fruit like measur year quarter
await visibl consensu number need move lower expect
see revis follow quarter beyond dynam bia
continu lean neutral-to-posit remain equal-weight updat
price target reflect mse ep discount large-cap
million except ep
good sold
million
million
million
million
million
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
sale
deriv base case scenario price target reect base-cas ep
discount larg cap peer
impact focu
view emphasi pipelin less
relev near-term upcom
denerv surgic robot
consensu number may need move
lower given outbreak
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
reset expect
execut organ growth trend
longer term new launch off-set
competit headwind ep growth
doubl digit aggress capit
deploy drive upsid
long-term prole mid-singl
digit organ growth bp
margin expans high-singl digit ep
growth total return prole
end market slow take top-line
organ growth fall
underli leverag harder come
given lower growth earn growth
reach mid upper singl digit
top-line growth estim bp
top-line growth contribut ep
margin estim bp ebit margin
drive ep
china india
view explan region hierarchi
research highest favor quintil
pipelin product approv launch
ahead expect
db tavr dcb linq
slowdown acceler emerg market
less repurchas activ materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
